Heather Weissman, MD
Ophthalmology · Atlanta, GANPI 1457641441
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Sight Sciences, Inc. accounts for 64.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $16,085 and has fallen 53.5% since, to $7,476 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $148.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$23K
- Bausch & Lomb Americas Inc.$3K
- Alcon$2K
- Glaukos Corporation$2K
- Shire North American Group Inc$2K
- Sun Pharmaceutical Industries Inc.$1K
- plus $4K from 18 others
What the payments were for
- Consulting fees$6,15017%
- Speaking & faculty fees$17,75050%
- Travel & lodging$8762%
- Food & beverage$10,92531%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 36 | $23,046 |
| Bausch & Lomb Americas Inc. | 30 | $2,883 |
| Alcon | 25 | $1,869 |
| Glaukos Corporation | 25 | $1,796 |
| Shire North American Group Inc | 3 | $1,541 |
| Sun Pharmaceutical Industries Inc. | 23 | $1,006 |
| AbbVie(2 entities) | 24 | $467 |
| Novartis | 11 | $373 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $353 |
| Oyster Point Pharma, Inc. | 10 | $315 |
| Rxsight Inc | 4 | $309 |
| Biotissue Holdings Inc. | 4 | $291 |
| Dompe US, Inc. | 6 | $257 |
| Eyepoint US, Inc. | 2 | $250 |
| Kala Pharmaceuticals, Inc. | 5 | $191 |
| Harrow Eye, LLC | 6 | $159 |
| Amgen(2 entities) | 2 | $150 |
| Genentech USA, Inc. | 1 | $130 |
| Carl Zeiss Meditec USA, Inc. | 1 | $128 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $75 |
| Akorn, Inc. | 2 | $55 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEARCARE SYSTEM$14,528
- TearCare SmartLid$5,039
- TEARCARE(TM) (2.2) SYSTEM KIT$5,039
- XIIDRA$3,317
- OMNI(R) SURGICAL SYSTEM (US)$3,147
- SION SURGICAL INSTRUMENT$3,000
- MIEBO$1,677
- Clareon$966
- CEQUA$356
- Hydrus Microstent$285
- Prokera$255
- AmnioGraft$255
- DEXYCU$250
- iDoseTR$194
- Clareon PanOptix Pro$175
- IACCESS$168
- iStent inject W$168
- ARGOS$141
- enVista MX60 IOL$138
- ENVISTA ENVY IOL$136
How this compares
$35,719 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 100 | $134,005 |
| RestasisCyclosporine | 33 | $47,265 |
| MieboPerfluorohexyloctane/Pf | 27 | $25,492 |
| Cyclosporine | 18 | $15,860 |
| Prednisolone Acetate | 232 | $11,804 |
| ProlensaBromfenac Sodium | 29 | $10,095 |
| Doxycycline Hyclate | 197 | $7,159 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 15 | $3,139 |
| Fluorometholone | 31 | $2,428 |
| Latanoprost | 114 | $1,492 |
| Ofloxacin | 105 | $1,375 |
| Loteprednol Etabonate | 11 | $1,238 |
| ValacyclovirValacyclovir Hcl | 17 | $866 |
| Timolol Maleate | 83 | $862 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $2,883 | $159,497127 claims |
| AbbVieRestasis | $467 | $47,26533 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $75 | $11,33340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.